Clinical outcomes of glaucoma treatment over a patient lifetime: A Markov model (letter) [2]

Journal of Glaucoma

Volumn 15, Issue 5, 2006, Pages 471-472

  Kymes, Steven ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COHORT ANALYSIS; GLAUCOMA; HUMAN; INTERVENTION STUDY; LETTER; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; STATISTICAL MODEL; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLINDNESS; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; LASER SURGERY; LASER THERAPY; MARKOV CHAINS; MODELS, BIOLOGICAL; MONTE CARLO METHOD; OCULAR HYPERTENSION; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY-ADJUSTED LIFE YEARS; SCOTOMA; SENSITIVITY AND SPECIFICITY; TRABECULECTOMY; VISUAL FIELDS;

EID: 33748938382     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ijg.0000212248.49337.1d     Document Type: Letter

References (5)

1. Nordmann JP, Lafuma A, Deschaseaux C, et al. Clinical outcomes of glaucoma treatments over a patient lifetime: a Markov model. J Glaucoma. 2005;14:463-469.
2. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in Health and Medicine. 1st ed. New York: Oxford University Press; 1996;425.
3. Quigley HA, Vitale S. Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci. 1997;38:83-91.
4. Investigators TA. The Advanced Glaucoma Intervention Study (AGIS) - 13. Comparison of Treatment Outcomes within Race: 10 Year Results. Ophthalmology. 2004;111:651-664.
5. Heijl A, Leske MC, Bengtsson B, et al. Measuring visual field progression in the Early Manifest Glaucoma Trial. Acta Ophthalmol Scand. 2003;81:286-293.